| Accession |
PRJCA016083 |
| Title |
SHR-1210-III-301-ESC:The PD-1 antibody SHR-1210 control investigator selection phase III study of chemotherapy in advanced or metastatic esophageal cancer |
| Relevance |
Medical |
| Data types |
clinical,image,Metabolic,Biomarker data
|
| Organisms |
Homo sapiens
|
| Description |
To evaluate the efficacy of camrelizumab versus investigator's choice of chemotherapy in patients with advanced or metastatic esophageal cancer after failure of first-line chemotherapy |
| Sample scope |
Multiisolate |
| Release date |
2023-04-06 |
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| NA
|
|
NA
|
|
|
|
| Submitter |
wanqiu
liang (wanqiu.liang@hengrui.com)
|
| Organization |
Jiangsu Hengrui Pharmaceutical Co. LTD |
| Submission date |
2023-04-06 |
